Gyan Chandra

Array ( [id] => 11311702 [patent_doc_number] => 20160347812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Novel Glucagon Analogues' [patent_app_type] => utility [patent_app_number] => 15/237958 [patent_app_country] => US [patent_app_date] => 2016-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 30534 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15237958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13067631 [patent_doc_number] => 10054592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay [patent_app_type] => utility [patent_app_number] => 15/236953 [patent_app_country] => US [patent_app_date] => 2016-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5986 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15236953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14280441 [patent_doc_number] => 20190137505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => BIOMARKERS OF METHYLGLYOXAL AND RELATED METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 15/751759 [patent_app_country] => US [patent_app_date] => 2016-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11434830 [patent_doc_number] => 20170035851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'Compositions And Methods For Treating Glioma' [patent_app_type] => utility [patent_app_number] => 15/232165 [patent_app_country] => US [patent_app_date] => 2016-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 27140 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15232165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13372487 [patent_doc_number] => 20180237784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => Therapeutic Agents [patent_app_type] => utility [patent_app_number] => 15/747292 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15747292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129253 [patent_doc_number] => 20160326228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS' [patent_app_type] => utility [patent_app_number] => 15/221341 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 33137 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15221341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11116370 [patent_doc_number] => 20160313344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'MRM/SRM Assay for Death Receptor 5 Protein' [patent_app_type] => utility [patent_app_number] => 15/211425 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6626 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15211425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13309849 [patent_doc_number] => 20180206461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => INHIBITING CTRP5 ACTION TO IMPROVE INSULIN RESISTANCE ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES [patent_app_type] => utility [patent_app_number] => 15/745625 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15745625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350220 [patent_doc_number] => 20160368960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/184116 [patent_app_country] => US [patent_app_date] => 2016-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20129 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15184116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568623 [patent_doc_number] => 20170107267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'PEPTIDE AGONISTS OF GLP-1 ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/183522 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 28978 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714425 [patent_doc_number] => 20170368167 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-12-28 [patent_title] => COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 15/174709 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714425 [patent_doc_number] => 20170368167 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-12-28 [patent_title] => COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 15/174709 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307360 [patent_doc_number] => 11208452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Insulins with polar recombinant extensions [patent_app_type] => utility [patent_app_number] => 15/577990 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 9 [patent_no_of_words] => 12094 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12016945 [patent_doc_number] => 09809638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Variant activin receptor' [patent_app_type] => utility [patent_app_number] => 15/171944 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 18437 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 299 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15171944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12165333 [patent_doc_number] => 09884092 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Methods for treating diabetes and reducing body weight' [patent_app_type] => utility [patent_app_number] => 15/168350 [patent_app_country] => US [patent_app_date] => 2016-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 33832 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15168350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259983 [patent_doc_number] => 10751392 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Pharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor agonist [patent_app_type] => utility [patent_app_number] => 15/577299 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 5384 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12191708 [patent_doc_number] => 09895422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-20 [patent_title] => 'Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders' [patent_app_type] => utility [patent_app_number] => 15/165485 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4600 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15165485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554204 [patent_doc_number] => 20170100450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE' [patent_app_type] => utility [patent_app_number] => 15/159412 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17918 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15159412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074300 [patent_doc_number] => 20160271263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'Acylated Glucagon Analogues' [patent_app_type] => utility [patent_app_number] => 15/155541 [patent_app_country] => US [patent_app_date] => 2016-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 43914 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15155541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269254 [patent_doc_number] => 20160331801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'USE OF CASPASE-2 INHIBITORS TO TREAT AND PREVENT THE METABOLIC SYNDROME' [patent_app_type] => utility [patent_app_number] => 15/151887 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 7511 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15151887 [rel_patent_id] =>[rel_patent_doc_number] =>)